International resistance testing guidelines updated

This article is more than 23 years old.

The International AIDS Society has updated its guidelines on resistance testing in HIV infection, first published at the beginning of 1999.

The only substantive difference with British HIV Association anti-retroviral treatment guidelines is the British recommendation that resistance testing should be carried out in all chronically affected patients prior to starting treatment.

Glossary

resistance testing

Laboratory testing to determine if an individual’s HIV strain is resistant to anti-HIV drugs. 

pharmacokinetics (PK)

How drugs are processed and used in the body, including how they are absorbed, metabolised, distributed and eliminated.

primary infection

In HIV, usually defined as the first six months of infection.

viral rebound

When a person on antiretroviral therapy (ART) has persistent, detectable levels of HIV in the blood after a period of undetectable levels. Causes of viral rebound can include drug resistance, poor adherence to an HIV treatment regimen or interrupting treatment.

viral breakthrough

An increase in viral load while on antiretroviral treatment.

IAS recommendations:

  • Consider resistance testing before starting treatment in areas where primary drug resistance is appreciable
  • Primary infection: all patients presenting with symptomatic primary HIV infection should be tested before commencing treatment, and also for surveillance purposes
  • First regimen failure: exclude poor adherence or PK problems, and obtain blood for resistance testing before stopping or changing the failing regimen. Resistance testing may not be necessary if the clinician is confident about the patient's treatment history and when the therapy switch occurs soon after treatment failure is identified whilst viral load is low [level not specified]
  • Resistance testing is likely to helpful (after excluding poor adherence or PK problems) where:

  1. A suboptimal response to first line treatment has occurred despite good adherence
  2. Viral breakthrough after an initially good response to therapy
  3. Viral rebound has been prolonged, thus permitting the accumulation of multiple resistance mutations

  • Subsequent regimen failures: resistance testing is recommended to guide therapy switches, in order to maximise the number of active drugs in the next regimen
  • Pregnancy: resistance testing is recommended if the mother has detectable viremia and any previous anti-retroviral experience, or where there is a high prevalence of resistant virus in the community/ primary infection with drug resistant virus.
  • References

    Hirsch MS et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Journal of the American Medical Association 283 (18): 2417-2426, 2000.